



Press release

Regulated information

THIRD QUARTER 2010 TRADING UPDATE

RECORD BACKLOG RE-LAUNCH OF THE BIO-ASSAYS ACTIVITY DISPOSAL PROCESS

Louvain-la-Neuve, Belgium, November 17, 2010 – Embargo until 5:40 PM (Belgium time)
IBA (Ion Beam Applications SA: Reuters IBAB.BR and Bloomberg IBAB.BB)

KEY FIGURES AND EVENTS

At the end of the 3d quarter, IBA reports the following elements:

EQUIPMENT

- The year-to-date turnover is still below the previous year by 9% but the forecasts for the future are excellent thanks to the recent order intake that leads to a record backlog of more than €270 million as well as an operating and maintenance contract portfolio that guarantees growing recurring revenues for the segment.
- In particular, in Protontherapy/Hadrontherapy, IBA was selected in 2010 to supply eight systems on the top of the additional order for Trento, Italy. Amongst those, 3 are firm orders booked in the current backlog:
 - Princeton, USA (Procure)
 - Krakow, Poland
 - Dimitrovgrad, Russia
- Dosimetry continues to show year-over-year growth in excess of 15 percent.

PHARMACEUTICALS

- Sales show growth above 5 percent compared with the third quarter of 2009.
- Following an improved offer from the potential partner, the process of selling a majority stake in the Bio-Assays business was restarted. This should result in the accounting reclassification of Bio-Assays assets as “held for sale”.
- The strategy of developing and marketing proprietary, high value-added products is being actively pursued, so far without significant obstacles. Filing of the application for approval of Redectane® is now scheduled for the second quarter of 2011, slightly later than initially announced.
- As previously reported, the investment required for preparation of new molecules market launch has a significant adverse effect on the operating margin of the segment.



Press release

Regulated information

IMPACT OF EURO STRENGTHENING

- The evolution of the euro vis-à-vis the other currencies to which IBA is most exposed (USD, GBP, CNY and SEK) had a significant impact on financial expenses. That impact combined with a quarter with relatively slow activity lead to slightly negative results at September 30, 2010.

BALANCE SHEET

- As of the date of this press release, Group net debt has been reduced substantially from June 30, 2010.

OUTLOOK

The company anticipates better operating results in 2010 than 2009 for the following reasons:

- Results for 2009 were strongly influenced by provisions for projects.
- Recent orders and the perspective for additional new ones should ensure steady activity over the next 12 to 36 months.
- The proton therapy facilities for which orders were received in 2006 and 2007 are gradually coming on line, triggering the associated service contracts, which will contribute to support operating margins.

However, while the company stands by its forecast of improved results, the process of bringing new, high value-added radio-pharmaceutical tracers to market will weigh on short to medium-term performance. Furthermore, this positive forecast does not reflect the potential effects of a reclassification of Bio-Assays business contribution in case of takeover by a third party investor

SHAREHOLDER CALENDAR

Announcement of results at December 31, 2010
First quarter 2011 trading update

March 15, 2011
May 11, 2011

Pursuant to the Royal Decree of November 14, 2007, IBA declares that this trading update was prepared by the chief executive officer (CEO) and the chief financial officer (CFO).

ABOUT IBA

Founded in 1986 in Louvain-la-Neuve, Belgium, IBA is primarily active in the medical industry. It develops and markets state-of-the-art equipment and radiopharmaceuticals for cancer diagnosis and treatment. Leveraging its scientific expertise, IBA also provides electron accelerators for industrial



Press release

Regulated information

sterilization and ionization. IBA is listed on the pan-European stock exchange Euronext and is included in its BEL Mid Index (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Website: <http://www.iba-worldwide.com>

Contact

IBA

Jean-Marc Bothy

Chief Financial Officer

Tel.: +32 10 47 58 90

Jean-Marc.Bothy@iba-group.com